Menu
Not yet recruiting NCT07271732

Songling Xuemaikang Capsules for Cerebral Small Vessel Disease

No phase Interventional Hypertension Cerebral Small Vessel Diseases

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Songling Xuemaikang Capsule, Songling Xuemaikang Capsule Placebo.
Who it may be relevant to
Registry conditions: Hypertension, Cerebral Small Vessel Diseases. Basic parameters: 55 years — 75 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Songling Xuemaikang Capsules for Cerebral Small Vessel Disease: A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study

Overview

Cerebral small vessel disease (CSVD) is a common age-related microvascular disease related to the slow accumulation of damage to small arteries, veins, and capillaries. Hypertension is a risk factor for cerebrovascular disease, and its damage to the vascular endothelium is one of the key contributing factors to the pathogenesis of CSVD. CSVD has an insidious onset, and patients may exhibit no clinical symptoms in the early stage. Common clinical manifestations of chronic CSVD include vascular dementia, depression, gait disturbance, and abnormalities in swallowing and urinary functions. There is currently no specific treatment for CSVD. Existing studies have shown that Songling Xuemaikang capsule (SXC) combined with antihypertensive drugs exerted significant effects on systolic blood pressure (SBP), diastolic blood pressure (DBP), 24-hour SBP, and 24-hour DBP, while also improving symptoms of hypertension. Animal experiments have demonstrated that SXC can reduce apoptosis and alleviate cerebral ischemia-reperfusion injury, exerting neuroprotective effects. Additionally, a previously completed multicenter, randomized, double-blind, non-inferiority-designed clinical trial by the team, conducted in patients with primary hypertension, showed that SXC were non-inferior to losartan potassium in reducing diastolic blood pressure. Therefore, exploring the therapeutic potential of SXC in CSVD is highly necessary. This project is a randomized, double-blind, placebo-controlled multicenter clinical study to investigate the clinical efficacy and safety of SXC in the treatment of hypertension with CSVD. A total of 90 subjects who met the subject screening criteria are planned to be enrolled, with 45 patients in the test group and 45 patients in the placebo group.

Interventions

  • Drug Songling Xuemaikang Capsule
    3 capsules/time, tid, p.o Duration of Treatment: 1 year (12 months)
  • Drug Songling Xuemaikang Capsule Placebo
    3 capsules/time, tid, p.o Duration of Treatment: 1 year (12 months)

Primary outcome measures

  • Changes in the volume of white matter hyperintensities at 1 year. [Time frame: 1 year]
Secondary outcome measures (12)
  • Change from baseline in Mini-Mental State Examination (MMSE) at 1 year; [Time frame: 1 year]
  • Change from baseline in Hamilton Anxiety Scale (HAMA) at 1 year; [Time frame: 1 year]
  • Change from baseline in Hamilton Depression Scale (HAMD) at 1 year; [Time frame: 1 year]
  • Change from baseline in Pittsburgh Sleep Quality Index (PSQI) at 1 year; [Time frame: 1 year]
  • Change from baseline in Barthel Index (BI) at 1 year; [Time frame: 1 year]
  • Feasibility of recruitment and retention [Time frame: 1 year]
  • Change from baseline in the symptom of hyperactivity of liver yang pattern at 1 year; [Time frame: 1 year]
  • Change from baseline in the mean 24h systolic blood pressure at 1 year; [Time frame: 1 year]
  • Change from baseline in the mean 24h diastolic blood pressure at 1 year; [Time frame: 1 year]
  • Change from baseline in the mean daytime systolic blood pressure at 1 year; [Time frame: 1 year]
  • Change from baseline in the mean daytime diastolic blood pressure at 1 year; [Time frame: 1 year]
  • Change from baseline in the mean nighttime systolic blood pressure at 1 year [Time frame: 1 year]

Eligibility criteria

Inclusion criteria

  • Age 55-75 years (both inclusive);
  • MRI has moderate to (1) severe white matter lesions (deep Fazekas score > 1 or paraventricular Fazekas score > 2 or modified Fazekas score > 1), or (2) mild white matter hyperintensity (deep Fazekas score = 1 or paraventricular Fazekas score = 2 or modified Fazekas score = 1) combined with more than 1 lacunar infarction;
  • History of essential hypertension; Hypertension is defined as SBP consistently greater than 140 mmHg and/or DBP consistently greater than 90 mmHg, or those requiring clinical antihypertensive treatment.
  • Meeting the diagnostic criteria for hyperactivity of liver yang pattern; Hyperactivity of liver yang pattern is defined as having at least three of the following six symptoms: headache, dizziness or vertigo, irritability, flushed face, red eyes, and yellow tongue coating.
  • Functional independence in daily living (Modified Rankin Scale ≤2);
  • Voluntary participation in the study and be willing to sign the Informed Consent Form.

Exclusion criteria

  • Patients with acute ischemic stroke or acute intracranial hemorrhage (e.g., epidural hematoma, subdural hematoma, subarachnoid hemorrhage, intracerebral hemorrhage, etc.) or a history of cerebral infarction (non-lacunar) or intracranial hemorrhage within the past 3 months;
  • Symptomatic stenosis of the middle cerebral artery and/or internal carotid artery (stenosis rate ≥50%), or asymptomatic stenosis of the middle cerebral artery and/or internal carotid artery (stenosis rate ≥70%);
  • Untreated cerebrovascular malformations or intracranial aneurysms (diameter >3 mm);
  • Significant non-vascular white matter lesions (e.g., multiple sclerosis, adult-onset leukoencephalopathy, metabolic encephalopathy, etc.);
  • Patients with a history of cognitive impairment due to other causes (e.g., normal pressure hydrocephalus, Alzheimer's disease, Parkinson's disease, multiple sclerosis, encephalitis, etc.);
  • A history of intracranial or intramedullary surgery within the past year;
  • Severe hepatic, renal, or cardiac insufficiency (ALT or AST >2 times the upper limit of normal, or serum creatinine >1.5 times the upper limit of normal, or New York Heart Association \[NYHA\] functional class III or IV);
  • Severe three-vessel coronary artery disease as shown by coronary computed tomography angiography or coronary angiography within 90 days or suffering from frequent angina;
  • Refractory hyperglycemia uncontrolled by medication (fasting blood glucose >10 mmol/L, or HbA1c >8.0%);
  • Patients with severe diseases such as cancer and a life expectancy of less than 2 years;
  • Patients with psychiatric disorders that affect study medication administration and evaluation;
  • Previous allergy or intolerance to Songling Xuemaikang Capsules;
  • Contraindications to MRI examination (e.g., claustrophobia, presence of an implantable pacemaker, etc.);
  • Patients unable to comply with follow-up examinations or other study procedures due to residential location or other reasons;
  • Participation in other clinical trial projects.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Quadruple blind
Primary purpose
Treatment

Study locations

China · 1 center
  • Dongzhimen Hospital, Beijing University of Chinese Medicine — Beijing

Identifiers

NCT: NCT07271732 · 2025DZMEC-188-02

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗